Are Peptides Legal in Australia? TGA Scheduling, Penalties, and Import Rules

Australia regulates peptides through the Therapeutic Goods Administration (TGA), the national authority responsible for assessing and monitoring therapeutic goods under the Therapeutic Goods Act 1989 (Cth). Any substance intended to have a therapeutic effect – whether marketed for healing, performance, weight loss, or anti-ageing – is classified as a therapeutic good and falls under TGA jurisdiction, regardless of how the seller labels it.

The TGA classifies substances through the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), commonly called the Poisons Standard. This legislative instrument, updated multiple times per year, assigns substances to numbered Schedules that determine how tightly they are controlled. State and territory governments then enforce these classifications through their own legislation, which is why penalties for the same offence vary depending on jurisdiction.

What Do the Schedule Numbers Mean?

Three scheduling tiers are directly relevant to peptides:

• Schedule 4 (Prescription Only Medicine) – Can only be obtained with a valid prescription from a registered Australian medical practitioner and dispensed by a licensed pharmacy. Possession without a prescription is illegal in all states and territories. This is where most research peptides sit, including BPC-157, TB-500, CJC-1295, Ipamorelin, and Sermorelin.
• Schedule 8 (Controlled Drug) – Subject to additional restrictions on manufacture, supply, distribution, and possession, with specialised prescribing authority required in most states. Human Growth Hormone (HGH) is classified as Schedule 8.
• Schedule 9 (Prohibited Substance) – May only be used for approved research purposes. Possession carries criminal penalties in every jurisdiction. Melanotan II was reclassified to Schedule 9 in February 2026.

BPC-157 is classified as Schedule 4 (Prescription Only) in Australia as of 1 June 2024. Australia was the first country in the world to specifically add BPC-157 to its national scheduling system.

The TGA’s scheduling decision (ACMS #43, November 2023, final decision published May 2024) was driven by 48 import referrals from the Australian Border Force received between July 2022 and 2024. The TGA stated that BPC-157 posed “a high risk of misuse within athletic, fitness, wellness and anti-ageing consumer markets.” The decision was supported by 21 of 22 public consultation responses. The committee also recommended an Appendix D listing, making possession without authority illegal.

Because BPC-157 is not registered on the Australian Register of Therapeutic Goods (ARTG), it cannot be legally prescribed through the standard prescribing pathway. The Schedule 4 classification means that possession without appropriate authorisation is a regulatory offence, but there is no approved product for a doctor to prescribe. The only theoretical access pathway is the TGA’s Special Access Scheme, which requires demonstrated clinical need and has significant compliance requirements.

Melanotan II was reclassified from Schedule 4 to Schedule 9 (Prohibited Substance) in February 2026, placing it in the same category as MDMA and heroin. This is the most severe scheduling action the TGA has taken against any peptide.

The TGA cited three factors in its decision: 89 adverse event reports submitted between 2022 and 2025 (including two melanoma diagnoses within 18 months of Melanotan II use), concerns about non-selective melanocortin receptor activation, and the widespread promotion of Melanotan II through social media influencers despite it being an unapproved substance. The TGA issued almost 12,000 takedown notifications to online platforms in the first half of the 2024-25 financial year alone, many related to Melanotan products.

No, not for personal use. Personal importation of Schedule 4 research peptides without TGA authorisation is prohibited. The TGA’s Personal Importation Scheme, which allows individuals to import certain prescription medicines in limited quantities for personal use, does not extend to unapproved substances.

The Australian Border Force routinely intercepts peptide shipments and refers them to TGA compliance for assessment. Customs officers do not verify Poisons Standard classifications at the border – they flag peptide shipments broadly and pass them to the TGA. Receiving a compliance notice creates a regulatory file that can complicate future legitimate import applications.

For Schedule 9 substances like Melanotan II, importation is prohibited under all circumstances except for formally approved research conducted by an authorised institution.

While the TGA sets scheduling classifications nationally through the Poisons Standard, enforcement and penalties are governed by state and territory legislation. The consequences for identical conduct can vary significantly depending on jurisdiction.

Supply offences attract significantly higher penalties than simple possession across all jurisdictions. The Peptide Clinics and Evolution Supplements Federal Court outcomes demonstrate the scale of penalties the Federal Court is prepared to impose on commercial-scale offenders.

The only peptide-based medicines that are unambiguously legal for human use in Australia are those registered on the Australian Register of Therapeutic Goods (ARTG). These have undergone formal TGA assessment for quality, safety, and efficacy.

The critical distinction: research peptides like BPC-157, TB-500, and Ipamorelin are Schedule 4 but are not on the ARTG. This means they cannot be legally prescribed through the standard pathway. Being scheduled does not mean being available – it means being controlled.

What About the Special Access Scheme?

The TGA’s Special Access Scheme (SAS) provides a narrow pathway for registered medical practitioners to access unapproved therapeutic goods for individual patients. The prescribing clinician must demonstrate that no suitable registered alternative exists, that there is a genuine clinical need, and that the patient has provided informed consent. The SAS is not a routine access pathway and is subject to TGA audit.

Peptide Clinics Pty Ltd (2018-2019)

The TGA commenced Federal Court proceedings against Peptide Clinics Pty Ltd in November 2018 for breaches of the Therapeutic Goods Act 1989 and the Therapeutic Goods Advertising Code 2015. On 23 July 2019, Justice Jagot ordered Peptide Clinics to pay AUD $10 million in penalties (Secretary Department of Health v Peptide Clinics Australia Pty Ltd [2019] FCA 1107). The Court found that Peptide Clinics had deliberately and recklessly advertised prescription-only medicines to consumers via its website, Facebook, Instagram, and telephone, and had created a false impression that medical practitioners were involved in the business. The company went into liquidation but the Court held that penalties were still appropriate as a public deterrent.

The Essendon Supplements Scandal (2013-2016)

The largest anti-doping case in Australian sporting history centred on the banned peptide Thymosin Beta-4 (TB-4). In January 2016, the Court of Arbitration for Sport (CAS 2015/A/4059, WADA v. Bellchambers et al.) upheld WADA’s appeal and found 34 current and former Essendon Football Club players guilty of being administered TB-4 during the 2012 season. All 34 received backdated two-year suspensions. Remarkably, none of the players returned a positive drug test – the case was built entirely on circumstantial and non-analytical evidence. The Club was separately fined AUD $2 million and barred from the 2013 finals series, and sports scientist Stephen Dank received a lifetime AFL ban. For the full Essendon narrative, including the supplements programme, consent processes, and regulatory aftermath, see our TB-500 research guide.

Border Seizures and Ongoing Operations

The TGA conducts targeted operations against domestic research peptide suppliers, including seizures and prosecutions. BPC-157 import interceptions by the Australian Border Force between 2022 and 2024 directly informed the June 2024 scheduling decision. The TGA’s April 2026 safety alert confirmed increased enforcement focus on unapproved peptides marketed for personal use.

The divergence is striking. While the US under HHS Secretary Kennedy is moving to restore compounding access to peptides like BPC-157 and TB-500, Australia has been moving in the opposite direction – scheduling more peptides, escalating enforcement, and increasing penalties. Australia was the first country to specifically schedule BPC-157, a position no other major jurisdiction has replicated.

• Wegovy PBS listing (expected mid-2026) – The PBAC recommended semaglutide (Wegovy) for PBS subsidisation in November 2025 for adults with established cardiovascular disease and obesity. If listed, this would significantly improve affordability for eligible Australians. The listing is pending price negotiation with Novo Nordisk.
• Tirzepatide PBS re-entry – Timeline remains uncertain following the November 2024 PBAC consideration. A previous application was rejected on cost-effectiveness grounds.
• Further SUSMP scheduling decisions – The Poisons Standard is updated multiple times per year. The TGA has indicated it is monitoring peptide use trends closely, and the trend toward scheduling additional compounds shows no sign of reversing.
• Impact of US regulatory divergence – The FDA’s PCAC review in July 2026 could widen the gap between US and Australian approaches. Whether the TGA adjusts its position in response remains to be seen, but it has historically charted an independent course from the FDA.

Can you buy peptides legally in Australia?

You can legally obtain TGA-approved peptide medicines like semaglutide (Ozempic) and tirzepatide (Mounjaro) with a valid prescription from a registered Australian medical practitioner. Research peptides like BPC-157, TB-500, and Ipamorelin cannot be legally purchased for personal use, even with a prescription, because they are not registered on the ARTG.

Is it illegal to possess peptides in Australia?

It depends on the peptide and the Schedule. Possessing Schedule 4 peptides (BPC-157, TB-500, CJC-1295, Ipamorelin) without appropriate authorisation is a regulatory offence with penalties varying by state. Possessing Schedule 9 substances (Melanotan II) without a research licence is a criminal offence. Possessing TGA-approved peptides with a valid prescription is legal.

Does “research use only” make it legal to buy peptides?

No. The TGA has made clear that “research use only” labelling does not create a legal safe harbour. Once a product is marketed in a way that implies therapeutic benefit, or once the pattern of sales suggests personal use rather than legitimate institutional research, it becomes a therapeutic good subject to the full regulatory framework. The TGA assesses real intent based on order volumes, shipping addresses, and documented research purposes.

Are peptides banned in Australian sport?

Many peptides are prohibited under the World Anti-Doping Agency (WADA) Prohibited List, enforced in Australia by Sport Integrity Australia. Growth hormone secretagogues (Ipamorelin, GHRP-6, MK-677), tissue repair peptides (TB-4), and other performance-related compounds are banned in and out of competition. Testing positive for a WADA-prohibited peptide can result in suspension or a permanent ban from sport, as the Essendon supplements scandal demonstrated when the entire squad faced two-year CAS suspensions.

Will Australia follow the US in loosening peptide restrictions?

There is no indication that the TGA intends to follow the FDA’s direction. As of May 2026, the TGA’s regulatory trajectory has been consistently toward tighter controls: BPC-157 was added to Schedule 4 in June 2024, Melanotan II was escalated to Schedule 9 in February 2026, and enforcement operations have intensified. The TGA has historically charted an independent regulatory course from both the FDA and the MHRA.